Trouble surfaced early in the joint meeting of the FDA's Arthritis Advisory Committee (AAC) and the Drug Safety and Risk Management Advisory Committee for Takeda Pharmaceuticals Co. Ltd. with the supplemental NDA for xanthine oxidase inhibitor (XOI) Uloric (febuxostat).